Pascal Soriot, AstraZeneca CEO (Raphael Lafargue/Abaca/Sipa USA(Sipa via AP Images)

September 1, 2020 07:26 AM EDTUpdated 10:44 AM

Covid-19 roundup: AstraZeneca launches 3rd US PhIII vaccine study with a vow to avoid 'cutting corners'

Max Gelman

Senior Editor

John Carroll

Editor & Founder

AstraZeneca has launched the final round of US testing for their closely-watched Oxford vaccine for Covid-19, taking the third spot in line just behind …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: AstraZeneca launches 3rd US PhIII vaccine study with a vow to avoid 'cutting corners'

Max Gelman

Senior Editor

John Carroll

Editor & Founder

Sign up to read this article for free.

Pfizer looking to sell hospital drugs unit — reports

AstraZeneca CEO reaffirms commitment to China following executive's detention

'Expertise is a real thing': FDA commissioner warns of political risk to agency

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Covid-19 roundup: As­traZeneca launch­es 3rd US PhI­II vac­cine study with a vow to avoid 'cut­ting cor­ner­s'

Senior Editor

Editor & Founder

Sign up to read this article for free.

Covid-19 roundup: AstraZeneca launches 3rd US PhIII vaccine study with a vow to avoid 'cutting corners'